

1.6M Moderna Doses Withdrawn in Japan Over Contamination

Company confirms reports of particulate matter in vials, but finds 'no safety issues'

By [Yumiko Urasaki](#) and [Yuko Nomura](#)

Global Research, August 30, 2021

[Nikkei Asia](#) 26 August 2021

Region: [Asia](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at [@crg_globalresearch](#).

About 1.6 million doses of Moderna’s coronavirus vaccine have been taken out of use in Japan because of contamination reported in some vials, the Ministry of Health, Labor and Welfare said early Thursday.

Several vaccination centers have reported that vaccine vials contained foreign matter, according to an announcement from the ministry, which added it will seek to minimize the impact of the withdrawal on the country’s inoculation program.

The ministry said later in the day that the substance that had been mixed in may have been metal. “It’s a substance that reacts to magnets,” a ministry official said. “It could be metal.”

Takeda Pharmaceutical handles distribution of the U.S.-developed Moderna vaccine in Japan.

Nasdaq-listed Moderna confirmed receiving “several complaints of particulate matter” in vaccine vials distributed in Japan but said it had found “no safety or efficacy issues” related to these reports.

“The company is investigating the reports and remains committed to working transparently and expeditiously with its partner, Takeda, and regulators to address any potential concerns,” a Moderna spokesperson told Nikkei, saying the drugmaker believed a “manufacturing issue” at a plant in Spain was the cause.

The vaccine lot in question and two adjacent lots have been put on hold “out of an abundance of caution,” the spokesperson said.

The Japanese ministry has not halted the use of Moderna vaccines in other batches, deeming them safe.

Prime Minister Yoshihide Suga told reporters on Thursday afternoon that he had instructed the ministry to look into the case with safety as the top priority, adding he had received

reports that the withdrawal “won’t have a significant impact on the country’s vaccination campaign.”

The Moderna vaccine was granted emergency-use authorization in Japan in May.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Children’s Health Defense

The original source of this article is [Nikkei Asia](#)
Copyright © [Yumiko Urasaki](#) and [Yuko Nomura](#), [Nikkei Asia](#), 2021

[**Comment on Global Research Articles on our Facebook page**](#)

[**Become a Member of Global Research**](#)

Articles by: [Yumiko Urasaki](#)
and [Yuko Nomura](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca